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specific inhibitor AG 490 effectively inhibited the IL-6–inducedSTAT3, but not ERKs, mediates the IL-6–induced proliferation
STAT3 activity and induced apoptosis, the blockade of theof renal cancer cells, ACHN and 769P.
STAT3 signaling pathways is considered to be potentially use-Background. Although interleukin-6 (IL-6) has been sug-
ful as a novel therapeutic approach for RCC.gested to function as an autocrine growth factor in renal cell
carcinoma (RCC), the underlying mechanism responsible for
the IL-6–induced proliferation of RCC has not been defined.
The aim of this study was to characterize the signaling cascades Interleukin-6 (IL-6) is a cytokine with pleiotropic ac-mediating IL-6–induced proliferation and to investigate the
tivities, including the induction of differentiation and theuse of effective novel interventions to block the IL-6–induced
regulation of growth in a cell-type dependent mannerautocrine growth of renal cancer cells.
Methods. IL-6–induced proliferation and intracellular signal- [1]. IL-6 initiates its action by binding to its receptor,
ing cascades were analyzed in four human renal cancer cell which is composed of two subunits: an 80-kD IL-6 bind-
lines Caki-1, ACHN, 769P and A498. IL-6–induced activation ing protein (gp80) and a 130-kD transmembrane signal-of STAT3 (signal transducer and activator of transcription-1)
transducing component (gp130) [2, 3]. The binding ofand extracellular signal-regulated kinases (ERKs), and the ef-
IL-6 to its receptor induces the dimerization of gp130,fects of anti–IL-6 neutralizing antibody, Jak inhibitor AG 490,
and MEK1 inhibitor PD 98059 were analyzed by Western blot- the activation of the gp130-associated protein tyrosine
ting using phospho-specific antibodies. The DNA-binding ac- kinases of the Janus kinase families (Jak1, Jak2 and
tivities of STATs were analyzed by EMSA. Apoptosis was deter- Tyk2) and the phosphorylation of gp130 at cytoplasmicmined by using nuclear staining and the TUNEL assay. Changes
tyrosine residues [4]. These phosphotyrosines serve asin the apoptosis-related proteins, bcl-2, bcl-xL, and bax were
docking sites for the SH2 domain containing proteinsanalyzed by Western blotting.
Results. IL-6 induced tyrosine phosphorylation and increased such as the signal transducers and activators of transcrip-
the DNA binding activity of STAT3 and, to a lesser extent, tion (STAT1 and STAT3) and the protein tyrosine phos-
STAT1 in all cell lines except for Caki-1, which did not express phatase (SHP2), which themselves subsequently becomethe IL-6 receptor subunit gp130. ERKs were constitutively ac-
tyrosine phosphorylated [4, 5].tivated in all cell lines and the activation level was not up-reg-
After tyrosine phosphorylation, STAT3 forms a homo-ulated further by exogenously added IL-6 nor down-regulated
by anti–IL-6 neutralizing antibody. IL-6–induced STAT3 tyro- dimer or a heterodimer with STAT1 and thereafter enters
sine phosphorylation and DNA binding activity was inhibited the nucleus, where it regulates the expression of specific
by treatment with Jak specific inhibitor AG 490; however, it genes. In addition to tyrosine phosphorylation, STAT3was not affected by the MEK1 inhibitor PD 98059. Moreover,
is serine phosphorylated at a single residue (Ser727) intreatment with AG 490 inhibited IL-6–induced proliferation
response to IL-6 [6]. Although tyrosine phosphorylationof ACHN and 769P cells and induced apoptosis with the down-
regulation of bcl-2 and the up-regulation of bax. has been shown to be essential for the dimerization, nu-
Conclusions. This study identified STAT3, but not ERKs, clear translocation and DNA binding of STAT3 [4], the
to be a major mediator of IL-6–induced proliferation of renal functional significance of Ser 727 phosphorylation ofcancer cells. Although ERKs were constitutively activated, ERKs
STAT3 remains controversial [6–8].were not found to be essential for the IL-6–induced prolifera-
On the other hand, SHP-2 has been shown to mediatetion and modulation of the STAT3 activity. Because the Jak
IL-6–induced signals to the extracellular signal-regulated
kinases (ERKs), which have been shown to play keyKey words: renal cell carcinoma, extracellular signal-regulated kinases,
roles in the intracellular signal transductions [5]. ERKsSTAT3, apoptosis, kidney cancer, cell proliferation, intracellular sig-
naling. are activated in a variety of cell types by diverse extracel-
lular stimulation and are among the most thoroughlyReceived for publication May 2, 2001
studied of the signaling pathways that connect differentand in revised form October 18, 2001
Accepted for publication October 22, 2001 membrane receptors to the nucleus [9].
In addition, recent studies have shown that STAT5 2002 by the International Society of Nephrology
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can be activated by IL-6 independently of the tyrosine ville, MD, USA). All cells were maintained in RPMI-
1640 supplemented 10% fetal bovine serum (FBS), 50phosphorylation of gp130 [10], while the stress-activated
protein kinase p38 is also activated by IL-6 [11]. Al- IU/mL penicillin and 50 g/mL streptomycin at 37C in
a humidified atmosphere with 5% CO2.though STAT3 and ERKs have been reported to be ma-
jor signaling pathways of IL-6, the molecules essential
Reagentsfor the cell proliferation induced by IL-6 vary depending
upon the cell type and the expression patterns of the Human recombinant IL-6 was purchased from Pep-
rotech (Rocky Hill, NJ, USA) and used at 20 ng/mL.signaling molecules [5, 12, 13]. Moreover, ERKs also
have been reported to play some role in the modulation Mouse monoclonal anti-human IL-6 neutralizing anti-
body (anti-IL-6 Ab) was obtained from R&D systemsof STAT3 activity [7, 8, 14, 15].
Despite extensive evaluations of many different treat- (Minneapolis, MN, USA). Jak inhibitor AG 490 and
MEK1 inhibitor PD 98059 were from Calbiochem (Lament modalities, metastatic renal cell carcinoma (RCC)
remains highly resistant to systemic therapy [16]. As a Jolla, CA, USA) and were solubilized in dimethylsulf-
oxide (DMSO) at 50 mmol/L, stored in the dark atresult, the identification of new agents with better anti-
tumor activity against metastases remains the highest pri- 70C. Phorbol 12-myristate 13-acetate (PMA), which
is a strong stimulator of ERKs, was from Calbiochem.ority in chemical studies of this refractory tumor. IL-6
has been suggested to function as an in vitro autocrine Rabbit polyclonal antibodies against STAT1, phospho-
specific STAT1 at Tyr701 (p-STAT1), STAT3, phospho-growth factor in RCC by demonstrating that primary
RCC expressed IL-6, and that their in vitro growth was specific STAT3 at Tyr705 (p-STAT3), phospho-specific
STAT5 at Tyr694 (p-STAT5), p38, phospho-specific p38inhibited by an anti–IL-6 antibody [17, 18]. Patients with
RCC often exhibit paraneoplastic syndrome, which in- at Thr180/Tyr182 (p-p38), ERKs, phospho-specific ERKs
at Thr202/Tyr204 (p-ERKs) were from New Englandcludes fever, leukocytosis, erythrocytosis, hypercalcemia
and an elevation of acute phase reactants. IL-6 has been Biolabs (Beverly, MA, USA). Mouse monoclonal anti-
bodies against STAT5, bcl-2, bcl-xL, bax, and mcl-1 werereported to be involved in the physiopathology of the
paraneoplastic syndromes [19]. Furthermore, the major- from BD Transduction Laboratories, Inc. (Franklin Lake,
NJ, USA). Mouse monoclonal antibody against -actinity of patients with metastatic RCC demonstrate increased
levels of serum IL-6 while patients with detectable serum was from DAKO (Tokyo, Japan).
IL-6 have poor survival [19]. These observations raise
Determination of IL-6 secretionthe possibility that pharmacological interventions to block
IL-6–induced autocrine growth may have therapeutic The cells were plated at 1  104 cells/well in six-well
plates in RPMI 1640 containing 10% FBS for 24 hours,potential in RCC. Unfortunately, the signaling mecha-
nism involved in the IL-6–mediated growth of RCC re- and then were washed with serum-free medium and cul-
tured for an additional 24 hours in 1 mL of the serummains to be elucidated.
In the present study, we characterized the signaling free medium. The medium was collected and clarified
by centrifugation at 3000  g. The levels of IL-6 in thecascades mediating the IL-6–induced proliferation in re-
nal cancer cells and investigated a novel pharmacological supernatants were analyzed by enzyme-linked immuno-
sorbent assay (ELISA) using the HS human IL-6 immu-intervention to block IL-6–induced growth. Our results
demonstrated that the response of renal cancer cells to noassay kit (R&D Systems).
IL-6 is most likely mediated by STAT3, but not ERKs.
RNA extraction and RT-PCR analysis forMoreover, ERKs were constitutively activated indepen-
IL-6 receptor gp80 and gp130 subunitsdently of IL-6 stimulation. In addition, ERK activity was
not essential for modulation of STAT3 tyrosine phos- For RT-PCR, total RNA was isolated from 1 107 cells
using Trizol according to the manufacturer’s instructionsphorylation and DNA-binding activity. We also demon-
strated that Jak inhibitor AG 490 effectively inhibited (Gibco Life Technology, Rockville, MD, USA). One mi-
crogram RNA was reverse transcribed by Molony mu-the IL-6–induced activation of STAT3 without any effect
on ERKs activity and induced apoptosis in renal cancer rine leukemia virus (MMLV) reverse transcriptase (Boeh-
ringer Mannheim, Mannheim, Germany) with hexamercells. Based on these findings, we postulate that a disrup-
tion of the IL-6–mediated signals to STAT3 is potentially random primer. For polymerase chain reaction (PCR),
2 L cDNA was amplified using each gene specific prim-useful as a novel therapeutic approach to RCC.
ers in a total volume of 50 L using 2 U Taq polymerase
(Boehringer Mannheim). After 35 cycles, 15 L aliquots
METHODS
were run on 1.5% agarose gels and stained with ethidium
Cell culture bromide. The nucleotide bases used were 5-ACC TAT
GAA GAT AGA CCA TCT AAA-3 as an upstreamFour established human renal cancer cell lines, Caki-1,
ACHN, 769P, and A498 were obtained from ATCC (Rock- primer and 5-GGT TCT ATA AAA TAT AGT ATA
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ATT-3 as a downstream primer for gp130, 5-ATG CTG labs) in binding buffer (10 mmol/L HEPES pH 8.0, 80
mmol/L NaCl, 1 mmol/L EDTA, 10% glycerol, 1 mmol/LGCC GTC GGC TGC GCG CTG-3 as an upstream
DTT) for 20 minutes at room temperature. The samplesprimer and 5-TCT GAG CTC AAA CCG TAG TCT-3
were separated on a non-denaturing 4% polyacrylamideas a downstream primer for gp80, and 5-TGA AGG
gel in 0.5% TBE. Thereafter, the gels were dried andTCG GAG TCA ACG GAT TTG GT-3 as an upstream
autoradiographed.primer and 5-CAT GTG GGC CAT GAG GTC CAC
CAC-3 as a downstream primer for GAPDH. The gp130,
Determination of cell viabilitygp80 and GAPDH product sizes were 720 bp, 768 bp
The effects of IL-6, anti-IL-6 Ab and AG 490 on celland 983 bp, respectively [20].
viability of renal cancer cells were determined by using
Western blotting crystal violet staining as described previously [21]. In
brief, the cells were plated into a flat-bottom 96-wellFor analyses of intracellular signals by IL-6 in renal
plates at 1  104 cells/200 L /well in triplicate in RPMI-cancer cells, the cells were starved for 24 hours in serum-
1640 with 10% FBS. Twenty-four hours later, the me-free RPMI-1640 and stimulated with IL-6 for the indi-
dium was changed to serum-free medium containing thecated time. The cells were put on ice and rinsed with
indicated reagents and incubated for the indicated time.ice-cold phosphate-buffered-saline (PBS) containing 100
After incubation, the plates were washed and cell viabil-mol/L Na3VO4, and lysed with cell lysis buffer [20 mmol/L
ity was determined by staining the plates with 0.2% crys-Tris pH 7.4, 150 mmol/L NaCl, 2 mmol/L ethylenediamine-
tal violet (in 2% ethanol).tetraacetic acid (EDTA), 1% NP-40, 50 mmol/L NaF,
10 g/mL aprotinin, 10 g/mL leupeptin, 1 mmol/L phe- Nuclear staining
nylmethylsulfonyl fluoride (PMSF), 1 mmol/L Na3VO4].
The cells were fixed with 4% paraformaldehyde for 30The extracts were clarified by centrifugation at 12,000
minutes at room temperature and stained with 1 mmol/Lr.p.m for five minutes. Lysates containing equal amounts
Hoechst 33258 (Sigma, St. Louis, MO, USA) for 10 min-of proteins were resolved by electrophoresis on 12%
utes at 37C. The morphology was observed under asodium dodecyl sulfate-polyacrylamide gel electropho-
fluorescence microscope at a 365-nm-wavelength excita-resis (SDS-PAGE) and then transferred to nitrocellulose
tion light.membrane (Bio-Rad Laboratory, Hercules, CA, USA).
The membranes were blocked with Tris-buffered saline TUNEL analysis
(TBS) containing 5% nonfat milk before incubation with
DNA fragmentation was detected using the TUNEL
primary antibodies. Immunoreactive bands were visual-
technique as described previously [22]. In brief, 1  106
ized with the amplified alkaline phosphatase system ac- cells were fixed in 1% paraformaldehyde, permeabilized
cording to the manufacturer’s instructions (Bio-Rad). in 70% ethanol, and stored at 20C. Breaks at 3-OH
For analyzing the effect of AG 490 and PD 98059 on DNA were detected by the TUNEL technique using the
the intracellular signals, the cells were pretreated with Apotag Plus Fluorescein (FITC) kit (Oncor, Gaithers-
serial dilutions of AG 490 (for 16 hours) or PD 98059 burg, MD, USA) according to the supplier’s instructions.
(for one hour) prior to stimulation with IL-6. For analyz- FITC-labeled cells were counterstained with propidium
ing the changes in the expression levels of apoptosis- iodide (PI; Sigma) and analyzed by flow cytometry using
related proteins, the cells were incubated with IL-6 in EPICS ALTRA flow cytometer (Beckman Coulter, Ful-
the presence of 100 mol/L AG 490 for the indicated lerton, CA, USA).
time. The cell lysates were prepared, and Western blot-
ting was performed in the same manner. Quantification of the immunoreactive bands and
statistical analysis
Electrophoretic mobility shift assay (EMSA)
The relative density of immunoreactive bands of apo-
Nuclear extracts were prepared in hypertonic buffer ptosis-related proteins on Western blotting was calcu-
[20 mmol/L HEPES pH 7.9, 420 mmol/L NaCl, 1 mmol/L lated using the Image 1.52 program (NIH, Bethesda, MD,
EDTA, 1 mmol/L egtazic acid (EGTA), 20% glycerol, USA). The unpaired t test was used to determine statisti-
20 mmol/L NaF, 1 mmol/L Na3VO4, 1 mmol/L Na4P2O7, cal differences. A P value of less than 0.05 was considered
1 mmol/L dithiothreitol (DTT), 0.5 mmol/L PMSF, 1 to indicate statistical significance.
g/mL aprotinin, 1g/mL leupeptin]. Twenty micrograms
of the supernatants were incubated with 2 g poly dI-dC
RESULTS(Amersham Pharmacia Biotech, Buckinghamshire, UK)
Production of IL-6 and expression of IL-6 receptorwith double-strand oligonucleotides for the consensus
subunits in renal cancer cellsbinding of sis-inducible-element (SIE; 5-GTG CAT TTC
CCG TAA ATC TTG TCT AGA-3) labeled with [-32P] First, the production of IL-6 into the culture medium
and the expression of IL-6 receptor subunits (gp80 anddATP by T4 polynucleotide kinase (New England Bio-
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gp130) were confirmed in renal cancer cells. Basal IL-6
secretion levels were determined using ELISA. Al-
though all cell lines exhibited detectable basal produc-
tion of IL-6 (35.3  13.8 pg/mL in Caki-1, 16.3  9.3
pg/mL in ACHN, 4.2  2.0 pg/mL in 769P, and 219 
37 pg/mL in A498, respectively), the levels of IL-6 pro-
duction varied widely depending upon the cell type
(Fig. 1A). Expression of mRNA for gp80 and gp130
was determined by the RT-PCR methods. The specific
product for gp80 subunit (768 bp) was observed in all
cell lines, whereas gp130 (720 bp) was expressed in
ACHN, 769P and A498, but not in Caki-1 (Fig. 1B).
Effect of exogenously added IL-6 and anti-IL-6 Ab on
the proliferation of renal cancer cells
The effects of exogenously added IL-6 and anti-IL-6
Ab on the proliferation of renal cancer cells were as-
sessed by crystal violet staining. According to the manu-
facturer’s specifications, 1.5 g/mL of the anti-IL-6 Ab
almost completely neutralized the biological activity due
to 20 ng/mL IL-6. Incubation with IL-6 increased ACHN
and 769P cells growth by 154.6  6.7% and 122.8 
7.1%, respectively, after 96 hours in comparison to the
untreated cells (P	 0.05; Fig. 1C). Moreover, preincuba-
tion with anti-IL6 Ab significantly inhibited IL-6–induced
cell proliferation of ACHN and 769P cells (P 	 0.05;
Fig. 1C). Although no significant proliferation by exoge-
nously added IL-6 was observed in A498 cells, anti-IL-6
Ab significantly inhibited proliferation compared with
untreated cells (P 	 0.05; Fig. 1C). In Caki-1, which did
not express gp130 mRNA, IL-6 and anti-IL-6 Ab had
no effect on the proliferation (Fig. 1C).
Analyses of intracellular signals of IL-6 in renal
cancer cells
The intracellular signaling pathways of IL-6 in renal
cancer cells were analyzed by Western blotting using
phospho-specific antibodies, which only detect the acti-
vated status. First, the effect of IL-6 on the tyrosine
phosphorylation levels of STAT1, STAT3 and STAT5
(STAT1 at Tyr701, STAT3 at Tyr705, and STAT5 at
Tyr694, respectively) was examined. To assess the phos-
phorylation levels of STAT proteins, starved cells were
either left unstimulated or were stimulated with IL-6
for 15 minutes. Total cell extracts were prepared and
Fig. 1. (A) Determination of interleukin-6 (IL-6) production in the subjected to Western blotting. Total STAT1, STAT3,culture medium by renal cancer cells. The level of IL-6 production was
and STAT5 proteins were present in all cell lines anddetermined using ELISA. Cells were seeded at equal densities (1 
104 cells/well) in 6-well plates. Next the cells were cultured for 24 hours the expression levels were not affected by IL-6 (Fig. 2A).
in serum free medium and the supernatants were analyzed with ELISA. IL-6 induced comparable tyrosine phosphorylation ofThe results represent the mean  SD of three separate experiments.
(B) RT-PCR analysis for the expression of the IL-6 receptor (gp80)
and gp130 mRNA in renal cancer cells. The gp130, gp80 and GAPDH
product sizes were 720 bp, 768 bp and 983 bp, respectively. GAPDH
was used as an internal control. (C ) Cell proliferation in response to
IL-6. Cells were incubated in the presence or absence of 20 ng/mL IL-6 viability was determined by crystal violet staining. Results represent the
with or without 1.5 g/mL anti-human IL-6 antibody (Ab) for 96 hours. mean  SD of three separate experiments. *P 	 0.05 compared with
Symbols are: () untreated; () IL-6; ( ) IL-6 
 anti-IL-6 Ab. Cell untreated cells. **P 	 0.05 compared with the cells treated with IL-6.
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Fig. 2. IL-6–mediated intracellular signaling cascades in renal cancer cells. Serum deprived cells were stimulated with 20 ng/mL IL-6 for 15
minutes. The phosphorylation levels of STAT1, STAT3, STAT5 (A), ERKs and p38 (B) were analyzed by western blotting using phospho-specific
antibodies, which detect only activated status. (C ) Serum deprived cells were untreated or treated with 100 ng/mL PMA for 10 minutes and the
phosphorylation level of ERKs was analyzed by Western blotting (D). The phosphorylation kinetics of STAT1, STAT3 and ERKs in ACHN cells
after stimulation with IL-6. Serum deprived cells were stimulated with IL-6 for 15 to 60 minutes and phosphorylation level was analyzed by
Western blotting.
STAT3 and, to a lesser extent, STAT1 in all cell lines STAT1, STAT3 and ERKs in response to IL-6, ACHN
cells were stimulated with IL-6 for 15 to 60 minutes andexcept for Caki-1, which did not express gp130 (Fig. 2A).
The amount of phosphorylated STAT1 seemed to be far the phosphorylation levels were analyzed by Western blot-
ting. The transient tyrosine phosphorylation of STAT3less than that of phosphorylated STAT3 because the
exposure time to detection reagents required to visualize and, to a lesser extent, STAT1 was observed within 15
minutes upon IL-6 stimulation in ACHN cells and re-the immunoreactive bands of phosphorylated STAT1 is
much longer than phosphorylated STAT3. IL-6 did not turned to near basal level within approximately 60 min-
utes, whereas the phosphorylation level of ERKs showedinduce tyrosine phosphorylation of STAT5 in all cell
lines (Fig. 2A). no changes from the unstimulated level at any periods
(Fig. 2D). The phosphorylation of STAT5 and p38 wasTo determine whether IL-6 activated the ERKs and
p38 cascades, their activation status was assessed by not observed at any period (data not shown). The same
results also were obtained for 769P cells (data not shown).Western blotting using antibodies that specifically recog-
nize the dually phosphorylated status (ERKs at Thr202/
Endogenous IL-6 produced by renal cancer cells wasTyr204 and p38 at Thr180/Tyr182, respectively). In all
not responsible for the constitutive activation of ERKscell lines, total ERKs and p38 were expressed at compa-
rable levels, which were not affected by IL-6 (Fig. 2B). Because ERKs have been shown to be a major media-
Interestingly, ERKs were constitutively activated in all tor of IL-6 signaling [5, 12] and renal cancer cells secreted
cell lines, which were not further up-regulated by stimu- detectable levels of IL-6 into a culture medium (Fig. 1A),
lation with exogenous IL-6 (Fig. 2B). A strong stimulator we questioned whether endogenous IL-6 produced by
for ERKs phosphorylation, PMA, increased ERK phos- renal cancer cells might be responsible for the constitu-
phorylation in Caki-1 and 769P cells, which strongly sup- tive activation of ERKs. We examined whether the neu-
port our results, indicating that IL-6 did not up-regulate tralization of endogenous IL-6 activity might lead to a
ERK phosphorylation (Fig. 2C). On the other hand, p38 decrease in the phosphorylation levels of ERKs. The
was not activated by IL-6 in any of the cell lines (Fig. 2B). starved ACHN and 769P cells were untreated, stimulated
with IL-6 for 15 minutes, cultured for 24 hours with anti-Furthermore, to study the phosphorylation kinetics of
Horiguchi et al: IL-6 and STAT3 in renal cancer 931
cording to the cell type and activation status [7, 8, 14,
15]. ERKs have been reported to potentiate the STAT3
activity through serine phosphorylation [8], while inhib-
iting the STAT3 activity upstream from tyrosine phos-
phorylation [15]. Since the ERKs were constitutively ac-
tivated in all cell lines in our experiments, we speculated
that ERKs was involved to some degree in the modula-
tion of STAT3 activity. To examine whether the inhibi-
tion of the ERK activity by PD 98059, which is a specificFig. 3. Neutralization of IL-6 did not reduce the phosphorylation levels
of extracellular signal-regulated kinases (ERKs). Serum deprived 769P inhibitor of MEK1, alter the level of IL-6–induced tyro-
and ACHN cells were untreated, stimulated with IL-6 for 15 minutes, sine phosphorylation of STAT3 in renal cancer cells,
cultured with anti-IL-6 Ab for 24 hours, or cultured with anti-IL-6 Ab
ACHN and 769P cells were exposed to various concen-for 24 hours prior to stimulation with IL-6 for 15 minutes. Cell lysates
were prepared and analyzed by western blotting. trations of PD 98059 one hour prior to stimulation with
IL-6. PD 98059 inhibited the constitutively activated
ERKs at 25 mol/L in both cell lines, whereas it didIL-6 Ab, or cultured for 24 hours with anti-IL-6 Ab prior
not affect the tyrosine phosphorylation levels of STAT3to stimulation with IL-6, and then the phosphorylation
induced by IL-6 even at 100 mol/L (Fig. 5). Theselevels of ERKs were analyzed by Western blotting. In
results indicate that the ERK activity is not essentialboth cell lines, the levels of ERKs phosphorylation were
for the modulation of STAT3 activation at the tyrosinenot down-regulated by treating the cells with anti-IL-6
phosphorylation level.Ab nor up-regulated by any subsequent stimulation with
exogenous IL-6 (Fig. 3). The same results also were seen
IL-6–induced STATs-DNA binding activity isin Caki-1 and A498 cells (data not shown). These results
inhibited by AG 490, but not by PD98059indicate that constitutive ERK phosphorylation does not
In addition to tyrosine phosphorylation, we examinedappear to be due to the endogenous IL-6 produced by
whether IL-6 increases the STATs-DNA binding activityrenal cancer cells.
and whether AG 490 or PD 98059 suppresses the DNA
The Jak-specific inhibitor AG 490 attenuated binding activity by EMSA using a 32P-labeled SIE probe,
IL-6–induced tyrosine phosphorylation of STAT3, which binds both activated STAT1 and STAT3 with a
but not constitutive phosphorylation of ERKs high affinity [23, 24]. The stimulation of ACHN and
Interleukin-6 leads to the homodimerization of gp130, 769P cells with IL-6 resulted in the rapid induction of a
which results in the activation of gp130-associated Jak1, STATs-DNA complex that binds the SIE oligonucleo-
Jak2 and Tyk2. Subsequently, gp130 is phosphorylated tides (Fig. 6). The IL-6–induced STATs-DNA binding
on tyrosine, and the phosphorylated molecule recruits activity was markedly inhibited by AG 490, but not PD
SHP2 and STAT3 [4, 5]. To investigate the involvement 98059, and this finding closely correlated with that of
of Jak kinase in IL-6–mediated signaling cascades in renal the tyrosine phosphorylation level (Fig. 6). These results
cancer cells, we examined whether treatment with the indicate that the ERK activity is not involved in the
Jak-specific inhibitor AG 490 attenuates the phosphory- modulation of the STAT3 activity at the nuclear trans-
lation levels of STAT3 and ERKs. ACHN and 769P cells location level.
were exposed to various concentrations of AG 490 16
hours prior to stimulation with IL-6. Preincubation with AG 490 suppressed the IL-6–induced proliferation of
AG 490 resulted in the inhibition of the IL-6–induced renal cancer cells
tyrosine phosphorylation of STAT3 at 25 mol/L in
Previous results indicated that IL-6 mainly activatesACHN cells and at 100 mol/L in 769P cells (upper
STAT3, while Jak inhibitor AG 490 effectively inhibitspanels, Fig. 4). On the other hand, the constitutive phos-
the IL-6–induced STAT3 tyrosine phosphorylation andphorylation of ERKs was not suppressed by AG 490,
DNA binding activity in ACHN and 769P cells. To studyeven at high concentrations (100 mol/L) in both cell
the functional consequences following the inhibition oflines (lower panels, Fig. 4). These results indicate that
IL-6 signaling by Jak inhibitor, the effect of AG 490 onJak kinase is essential for the IL-6–induced activation of
IL-6–induced proliferation of renal cancer cells was testedSTAT3, but not for the constitutive activation of ERKs in
on ACHN and 769P cells that had been treated with IL-6renal cancer cells.
in the presence or absence of AG 490 at serial concentra-
Inhibition of constitutively activated ERKs by the tions for 96 hours. The proliferation of both cell lines
MEK1 inhibitor PD 98059 did not modulate the was significantly suppressed following AG 490 treatment
IL-6–induced tyrosine phosphorylation of STAT3 in a dose dependent manner (Fig. 7). The proliferation
of ACHN cells was significantly suppressed by AG 490The functional significance of ERKs in the modulation
of the STAT3 activity has been reported to vary ac- at a concentration 1 mol/L, with IC50  0.5 mol/L
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Fig. 4. Effect of the Jak inhibitor AG 490 on
the phosphorylation of STAT3 and ERKs in
IL-6–stimulated renal cancer cells (RCC). Se-
rum deprived 769P and ACHN cells were un-
treated, stimulated with IL-6 for 15 minutes,
or treated with serial concentration of AG 490
for 16 hours prior to stimulation with IL-6 for
15 minutes. Cell lysates were prepared and
subjected to Western blotting.
Fig. 5. Effect of MEK1 inhibitor PD 98059
on the phosphorylation of STAT3 and ERKs
in IL-6–stimulated renal cancer cells. Serum-
deprived 769P and ACHN cells were un-
treated, stimulated with IL-6 for 15 minutes,
or treated with serial concentration of PD
98059 for 1 hour prior to stimulation with IL-6
for 15 minutes. Cell lysates were prepared and
subjected to Western blotting.
and 769P cells also was suppressed at a concentration
1.0mol/L, with an IC50 3.5mol/L. The toxic effects
from the solvent used to dissolve AG 490 could be ex-
cluded since the cells incubated with the highest concen-
tration of DMSO, which was equivalent to 100 mol/L
AG 490, showed no significant growth inhibition (data
not shown). To examine any other effects of AG 490, the
effects of AG 490 on the proliferation of 769P and ACHN
cells were examined without IL-6 stimulation, which re-
sulted in significant growth suppression (data not shown).
Fig. 6. AG 490, but not PD 98059 inhibited increased STATs-DNAHowever, under non-stimulated conditions, the concen- binding activity by IL-6 in ACHN and 769P cells. Serum-deprived 769P
tration of AG 490 required to significantly suppress the and ACHN cells were untreated, stimulated with IL-6, or incubated
with 100 mol/L AG 490 for 16 hours or 100 mol/L PD 98059 for onespontaneous growth was higher than IL-6–stimulated
hour prior to stimulation with IL-6 for 15 minutes. Nuclear extracts were
condition (IC50  10.0 mol/L in both cells). In addition, incubated with the 32P-labeled SIE oligonucleotide probe, which binds
both activated STAT1 and STAT3, and then were analyzed by EMSA.AG 490 suppressed proliferation of Caki-1 cells, which
The positions of STAT3 homodimer (ST3/3), STAT1/STAT3 hetero-had no proliferative response to IL-6 (data not shown). dimer (ST1/3), STAT1 homodimer (ST1/1), are indicated on the left.
However, the concentration of AG 490 required to sup-
press proliferation of Caki-1 cells also is much higher
than to suppress the IL-6–driven proliferation of 769P
AG 490 induced apoptosis in renal cancer cellsand ACHN cells (IC50 value  30.0 mol/L in Caki-1
cells). Based on these results, the spontaneous and IL-6– Activated STAT3 signaling has been shown to prevent
induced growth of renal cancer cells seems to be me- apoptosis [13, 26, 27], and to determine whether the in-
diated by at least partly distinct pathways with different hibition of IL-6–induced signals by AG 490 may lead to
sensitivities to AG 490. Similar results indicating different apoptotic cell death, nuclear staining was done using a
sensitivities to AG 490 between cytokine-driven growth Hoechst 33258 and a flow cytometric TUNEL assay, both
and spontaneous growth have been reported in another of which are useful methods for detecting apoptosis.
ACHN cells were either untreated or incubated with IL-6study [25].
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in the absence or the presence of 100 mol/L AG 490
for 96 hours and then stained with the DNA-specific
fluorescent dye Hoechst 33258 for morphological ex-
amination. The nuclei of the cells treated with IL-6 in
the presence of AG 490 appeared lobated and severely
fragmented and contained highly condensed chromatin
(Fig. 8A), which are characteristic findings of apoptosis.
Furthermore, AG 490-induced apoptosis also was con-
firmed by a flow cytometric TUNEL assay. The untreated
cells and cells cultured with IL-6 in the absence of AG490
showed apoptosis in only 0.8% and 0.4% of cells, respec-
tively, whereas the cells cultured with IL-6 in the presence
of 100 mol/L AG 490 showed apoptosis in 34.9% of cells
(Fig. 8B). These apoptosis-inducing effects were observed
in 769P cells as well (data not shown).
Changes in apoptosis-related proteins levels in
AG 490 induced apoptosis
To further clarify the mechanisms underlying the AG
490-induced apoptosis of renal cancer cells, we examined
whether AG 490 induces apoptosis by modulating the
expression of apoptosis-related proteins, bcl-2, bcl-xL,
mcl-1, and bax by Western blotting. ACHN cells were in-
cubated with IL-6 in the presence of 100 mol/L AG 490
for the indicated times and thereafter were subjected to
Western blotting. Although the bcl-2 and bax proteins
were expressed at basal levels in ACHN, the expression
of bcl-xL protein was very modest (Fig. 9) and mcl-1
could not be detected (data not shown). The inhibition
of the Jak kinase activity by AG 490 resulted in the
down-regulation of bcl-2 by 66.9% and the up-regulation
of bax by 153.5% following 96 hours of treatment com-
pared with the basal levels (Fig. 9). On the other hand,
the expression of bcl-xL did not change (Fig. 9).
DISCUSSION
Although IL-6 has been shown to play an important
role in the proliferation of RCC [17–19], the molecular
basis for IL-6–mediated signaling cascades has not been
previously investigated. To the best of our knowledge,
this is the first report that characterized the signaling
cascades mediating the IL-6–induced proliferation of re-
nal cancer cells.
The present study first confirms the role of IL-6 in the
proliferation of renal cancer cells. In our experiments,
a significant IL-6–induced proliferation was observed inFig. 7. Effects of AG 490 on the proliferation of renal cancer cells in
response to IL-6. ACHN (A) and 769P (B) cells were plated into a flat- ACHN and 769P cells. Although A498 cells produced
bottom 96-well plates at 1  104 cells/200 L/well in RPMI-1640 with IL-6 at higher levels than other cells and expressed both
10% FBS. Twenty-four hours later, medium was changed to serum-free
IL-6 receptor subunits, no significant IL-6–induced pro-medium with or without IL-6 in the presence or absence of the indicated
concentrations of AG 490 and incubated for 96 hours. The cell viabilities liferation was observed at 20.0 ng/mL. The result that
were determined by using crystal violet staining. The results are shown the anti-IL-6 antibody suppressed proliferation of A498
as the mean  SD of triplicate cultures. *P 	 0.05 compared with
cells under non-stimulated as well as IL-6 stimulated con-untreated cells. **P 	 0.01 compared with untreated cells.
dition suggests that the proliferation of A498 cells de-
pends at least in part upon IL-6. In our additional experi-
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Fig. 8. AG490 induced apoptosis in ACHN cells. ACHN cells were
untreated (a), treated with IL-6 (b), or treated with IL-6 in the presence
of 100 mol/L AG 490 (c) for 96 hours. (A) Fluorescence photomicro-
graphs of ACHN cells stained with Hoechst 33258. The cells treated
with IL-6 in the presence of 100 mol/L AG 490 showed the presence
of fragmented and condensed nuclei, which is characteristic of apoptosis.
Original magnification 320. (B) Induction of apoptosis determined
by flow cytometric TUNEL analysis in ACHN cells. The histogram
shows the percentage of cells with DNA double-strand break. The cells
with log fluorescence intensity 101 were considered to be positive for
apoptosis.
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in A498 cells up to 20 ng/mL. The lack of gp130 mRNA
expression, which is essential for IL-6–mediated signal-
ing [2, 3], could account for the unresponsiveness of
Caki-1 to IL-6 and anti-IL-6 Ab. From these results, we
confirmed that IL-6 acts as an autocrine or paracrine
growth factor in renal cancer cells and these findings
closely correlate with those of previous studies [17, 18].
To investigate which molecules were involved in the
IL-6–mediated proliferation of renal cancer cells, we
took into consideration that IL-6 acts as a growth factor
for a variety of malignant tumors, in addition to RCC
[12, 13, 20, 29]. Although STAT3 and ERKs have been
reported to be major signaling pathways of IL-6 and
recent studies showed that STAT5 and stress-activated
protein kinase p38 are also activated by IL-6, the cas-
cades mediating IL-6–induced growth vary depending
upon the cell type. For example, in a B9 murine IL-6–
dependent hybridoma cell line and some human multiple
myeloma cells, the activation of STAT3 occurs indepen-
dently of the proliferative response to IL-6, and their
growth depends upon the activation of ERKs [12]. On the
other hand, IL-6 stimulates prostate cancer cell growth
accompanied by the activation of the STAT3 signaling
pathway [29]. Moreover, STAT3 signaling is essential
for the survival of IL-6–dependent human myeloma cell
line, U266 cells [13]. In our experiments, IL-6 induced
tyrosine phosphorylation and DNA binding activity of
STAT3 and, to a lesser extent, STAT1 in all cell lines
except for Caki-1 without any expression of gp130. We
cannot completely exclude the possibility that STAT1
might contribute to IL-6–driven proliferation. However,
recent studies revealed that STAT1 actually has tumor
Fig. 9. (A) Western blot analysis for apoptosis-associated proteins bcl-2, suppressor functions and loss of STAT1 signaling enhances
bcl-xl, and bax. ACHN cells were cultured with IL-6 in the presence
oncogenesis [30–32]. On the other hand, STAT3 is believedof 100 mol/L AG 490 for the indicated periods. Whole cell lysates
were prepared and subjected to western blotting. -actin was used as to play an important role in the unrestrained growth of
an internal control. (B) The relative intensity of the immunoreactive many human tumors. This may be a plausible explana-
bands of () bcl-2; () bcl-xL; () bax; () -actin in comparison to
tion for our results in which the growth inhibitory effectsthe basal levels.
of activated STAT1 can be overcome by the simultane-
ous activation of STAT3, which resulted in cell prolifera-
tion. The activation of STAT3 was attenuated by treat-
ments, the proliferation of A498 cells was significantly ment with Jak inhibitor AG490 in ACHN and 769P cells,
stimulated by exogenous IL-6 at a tenfold higher concen- which proliferated by IL-6. The IL-6–induced prolifera-
tration (200.0 ng/mL). According to various reports, IL-6 tion of ACHN and 769P cells was significantly inhibited
exerts its biological activity in the concentration range by AG 490. Although STAT5 and p38 were expressed
of 0.1 ng/mL to 100.0 ng/mL, which is considered to be a in all cells, their activation was not observed after stimu-
physiological range [12, 15, 20, 28]. In fact, the serum IL-6 lation with IL-6. On the other hand, ERKs were constitu-
levels in patients with RCC have been reported between tively activated in all cell lines, even in Caki-1 cells, which
1 pg/mL to 1850 pg/mL [19]. As a result, the exogenous did not express gp130, and the activation level of ERKs
IL-6–driven proliferation of A498 cells seems to be ob- was not further up-regulated by exogenously added IL-6
served only under non-physiological conditions. A possi- nor down-regulated by anti-IL-6 Ab. Furthermore, the
ble explanation for IL-6–induced STAT3 activation with- inhibition of IL-6–mediated signal at the Jak kinase level
out a proliferative response is that activation level of by AG 490 did not decrease the degree of ERK phos-
STAT3 might be insufficient for the IL-6–driven prolifer- phorylation. Based on these findings, we conclude that
ation up to 20 ng/mL or that IL-6–induced activation of STAT3, but not ERKs, mediates the IL-6–induced pro-
liferation of renal cancer cells.STAT3 might be independent of the growth stimulation
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The exact mechanism underlying the constitutive acti- because of its absence of any effects on other tyrosine
kinases such as Lck, Lyn, Btk, Syk, or Src [36]. Recentvation of ERKs in RCC is not known at present. The con-
stitutive activation of ERKs has been shown to occur in studies revealed that AG 490 inhibit Jak1 and Jak3, in
addition to Jak2, all of which are closely related membersthe majority of RCC and the levels of activated ERKs
increased with increasing tumor grade and stage [33]. of the Jak kinase families [37, 38]. However, no other
additional AG 490-inhibited kinases have been reportedERKs are activated by a variety of mitogens such as
epidermal growth factor (EGF) and transforming growth and AG 490 does not inhibit growth of Jak-negative
Jurkat cells and Bcr-Abl fusion protein positive K562factor (TGF)- [34]. In addition to IL-6, EGF and TGF-
stimulate the growth of renal cancer cell lines in an auto- cells, and these findings strongly support the specificity
of AG 490 to Jak kinase [37, 39]. We cannot completelycrine manner [35]. We speculate that such growth factors
produced by renal cancer cells may be, at least in part, exclude the possibility that AG 490 inhibits signaling
cascades other than STAT3. Because AG 490 is likelyresponsible for the constitutive activation of ERKs.
Studies have revealed that ERKs were involved in the to be a Jak specific inhibitor, it may inhibit any other
several downstream molecules that are associated withmodulation of STAT3 activity [7, 8, 14, 15]. ERKs were
reported to potentiate STAT3 activity through serine Jak kinase. In addition to STAT3, to date several signal-
ing pathways are inhibited by AG 490, such as STAT5phosphorylation [8], as well as to inhibit the STAT3 ac-
tivity upstream of tyrosine phosphorylation [15]. The rel- and ERKs [37, 38]. However, we showed that STAT5 is
not activated in either basal or IL-6–stimulated condi-ative intensity of ERKs activity determines the modula-
tion of the STAT3 activity [7]. Although ERKs were tions and that constitutively activated ERKs were not in-
hibited by AG 490 even at 100 mol/L. Thus, the possi-constitutively activated independently of IL-6, we specu-
lated ERKs plays some role in the modulation of the bility that AG 490 might inhibit additional signals, at
least for STAT5 and ERKs, can be excluded. In addition,STAT3 activity. We therefore investigated the role of
ERKs in relation to the modulation of STAT3 activity at the effects of AG 490 on the spontaneous growth of renal
cancer cells resulted in significant growth suppression.the level of tyrosine phosphorylation and DNA binding
activity by using the MEK1 inhibitor PD 98059. Since the However, the concentration required to suppress the
spontaneous growth was much higher than that requiredinhibition of the ERK activity by PD 98059 did not mod-
ulate the tyrosine phosphorylation or the DNA binding to suppress the IL-6–induced growth. Similar results in-
dicating different sensitivities to AG 490 between cyto-activity of STAT3 in renal cancer cells, we conclude that
the ERK activity is not essential for the modulation of kine-driven growth and spontaneous growth were reported
in another study [25]. We speculate that the differencethe IL-6–induced STAT3 activation.
The ERK and STAT3 signaling pathways have been between the concentrations of AG 490 required to sup-
press spontaneous growth and IL-6–driven growth is dueshown to be essential for IL-6–mediated cell prolifera-
tion in other cells [5]. The ERK activation was shown to to the difference between the basal and IL-6–induced
Jak kinase activity. Based on these findings, we believebe essential for mitogenic signals, while, on the other hand,
the STAT3 activation has been shown to be involved in that AG 490-induced apoptosis is mediated, at least in
part, by an inhibition of STAT3 activity.the anti-apoptotic signals [5]. Accumulating evidence sug-
gests that the STAT3-mediated inhibition of apoptosis Recent studies showed that AG 490 has been shown to
block activation of STAT3 and growth of various cancermay be caused by the regulation of apoptotic regulatory
proteins, such as anti-apoptotic protein bcl-2 and bcl-xL cells by the induction of apoptosis [13, 25, 29]. Therefore,
we investigated whether the inhibition of IL-6–induced[27]. Moreover, STAT3 regulates the transcription from
the bcl-x promoter [13], and cells transformed by consti- STAT3 activation by the Jak inhibitor AG 490 subse-
quently leads to an inhibition of cell proliferation bytutively activated STAT3 also have elevated levels of
bcl-xL mRNA [26]. Because we demonstrated that STAT3, induction of apoptosis with a modulation of anti-apo-
ptotic proteins bcl-2, bcl-XL, mcl-1 and the pro-apoptoticbut not ERKs, mediated the IL-6–induced proliferation
of renal cancer cells, we speculated IL-6 might induce protein bax. In line with previous reports, AG 490 in-
hibited both the IL-6–induced STAT3 activation andcell proliferation by preventing apoptosis via the STAT3
signaling pathway. IL-6–triggered proliferation of ACHN and 769P cells by
the induction of apoptosis with a down-regulation ofAG 490, a newly identified Jak inhibitor, was first shown
to inhibit active DNA synthesis and it blocks the growth bcl-2 and up-regulation of bax. Whereas the changes in
their expressions by AG 490 were very modest, otherof recurrent pre-B-cell acute lymphoblastic leukemia
cells in which Jak2 is constitutively activated both in vitro apoptosis-related proteins may be involved. The anti-
apoptotic proteins bcl-2, bcl-xL, and mcl-1 have all beenand in vivo by inducing apoptosis [36]. The efficacy of
AG 490 in vivo is accompanied by a complete absence shown to be capable of binding to pro-apoptotic protein
bax and suppressing bax-induced apoptosis [40]. Amongof toxicity to normal blood cells [36]. It has been demon-
strated that AG 490 is not a general kinase inhibitor the bcl-2 family proteins, bcl-2 is frequently expressed
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tively modulates its tyrosine phosphorylation. Mol Cell Biol 17:in RCC, and a bcl-2 overexpression may explain the
6508–6516, 1997
relative resistance of RCC to conventional chemother- 8. Ng J, Cantrell D: STAT3 is a serine kinase target in T lympho-
cytes. Interleukin 2 and T cell antigen receptor signals convergeapy and radiotherapy [41, 42]. Unfortunately, the regula-
upon serine 727. J Biol Chem 272:24542–24549, 1997tion of the expression of bcl-2 family proteins in RCC
9. Widmann C, Gibson S, Jarpe MB, Johnson GL: Mitogen-activated
is still poorly understood. Because Jak inhibitor AG 490 protein kinase: Conservation of a three-kinase module from yeast
to human. Physiol Rev 79:143–180, 1999inhibited the IL-6–induced STAT3 activation followed
10. Fujitani Y, Hibi M, Fukada T, et al: An alternative pathway forby a reduction in bcl-2 expression, we speculate that the
STAT activation that is mediated by the direct interaction between
expression of bcl-2 may be regulated, at least in part, by JAK and STAT. Oncogene 14:751–761, 1997
11. Zauberman A, Zipori D, Krupsky M, Ben-Levy R: Stress activatedSTAT3 in RCC.
protein kinase p38 is involved in IL-6 induced transcriptional acti-A surgical resection of the primary localized RCC
vation of STAT3. Oncogene 18:3886–3893, 1999
remains the mainstay of therapy and metastatic RCC 12. Ogata A, Chauhan D, Teoh G, et al: IL-6 triggers cell growth
via the Ras-dependent mitogen-activated protein kinase cascade.is highly refractory to conventional therapies including
J Immunol 159:2212–2221, 1997radiation and chemotherapy [16]. As a result, the man-
13. Catlett-Falcone R, Landowski TH, Oshiro MM, et al: Constitu-
agement of advanced RCC remains a significant chal- tive activation of Stat3 signaling confers resistance to apoptosis in
human U266 myeloma cells. Immunity 10:105–115, 1999lenge to clinicians. Our results predict that blocking the
14. David M, Petricoin E, Benjamin C, et al: Requirement for MAPIL-6–induced signaling by inhibiting STAT3 activity will kinase (ERK2) activity in interferon alpha- and interferon beta-
not only block tumor growth by inducing apoptosis, but stimulated gene expression through STAT proteins. Science 269:
1721–1723, 1995also may increase the sensitivity of tumors to conven-
15. Sengupta TK, Talbot ES, Scherle PA, Ivashkiv LB: Rapid in-tional chemotherapy and radiation therapy by a reduc- hibition of interleukin-6 signaling and Stat3 activation mediated
tion of the anti-apoptotic proteins, such as bcl-2. by mitogen-activated protein kinases. Proc Natl Acad Sci USA 95:
11107–11112, 1998In summary, we identified STAT3, but not ERKs, to
16. Motzer RJ, Russo P: Systemic therapy for renal cell carcinoma.be a major mediator of IL-6–induced proliferation of J Urol 163:408–417, 2000
renal cancer cells. Although ERKs were constitutively 17. Gogusev J, Augusti M, Chretien Y, Droz D: Interleukin-6 and
TNF alpha production in human renal cell carcinoma. Kidney Intactivated, ERKs were not essential for the IL-6–induced
44:585–592, 1993proliferation and modulation of STAT3 activity. Because 18. Miki S, Iwano M, Miki Y, et al: Interleukin-6 (IL-6) functions as
the Jak-specific inhibitor AG 490 effectively inhibited an in vitro autocrine growth factor in renal cell carcinomas. FEBS
Lett 250:607–610, 1989IL-6-induced STAT3 activity and induced apoptosis, the
19. Blay JY, Rossi JF, Wijdenes J, et al: Role of interleukin-6 in theblockade of the STAT3 signaling pathway may be an paraneoplastic inflammatory syndrome associated with renal-cell
effective and novel therapeutic approach for RCC. carcinoma. Int J Cancer 72:424–430, 1997
20. Okamoto M, Lee C, Oyasu R: Interleukin-6 as a paracrine and
autocrine growth factor in human prostatic carcinoma cells in vitro.
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